MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
MediciNova presented new data and results from its Phase 1b/2a clinical trial of MN-166 at the ASCO meeting. The combination of Temozolomide (TMZ) and MN-166 was found to be safe and well tolerated, with no unexpected adverse effects. Preclinical data also showed improved survival with the combination of Ibudilast and PD-1 or PD-L1 antibody therapy.
June 03, 2024 | 10:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MediciNova's Phase 1b/2a trial of MN-166 demonstrated safety and tolerability, with no unexpected adverse effects. Preclinical data suggests potential benefits of combining Ibudilast with PD-1/PD-L1 antibody therapy.
The positive safety and tolerability results from the Phase 1b/2a trial of MN-166, along with promising preclinical data, are likely to boost investor confidence in MediciNova. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100